Splenocytes from low-dose (40 mg.kg-~.day-9
Diabetes induced in mice by multiple low-doses of streptozotocin (SZ) [1] depends on immune pathogenetical components [2] , and thus is a model used for the study of human Type 1 (insulin-dependent) diabetes. Cell-mediated immunity seems to be of major importance in this animal model [2] , while the role of humoral immunity appears minor since B lymphocyte-depleted mice retained their susceptibility to the disease [3] . This role of cellular immunity is established in vivo by the prevention of SZ-induced diabetes following injections of monoclonal antibodies directed against lymphocyte differentiation antigens [4, 5] . These studies have pointed out the implication of T-lymphocytes bearing either L3T4 or Lyt2 antigens, which have also been characterized in "insulitis" [4, 6] . Moreover, the presence of an anti-B cell specific cellular immunity is suggested in SZ-induced diabetes by in vitro cytotoxicity [7, 8] and in vivo pancreatic "homing" [9] experiments.
We have recently reported that anti-B-cell cell-mediated immunity could be detected, in a "rosette-forming cell" assay, by an increased B-cell specific binding of circulating T-lymphocytes during human recent-onset Type i diabetes [10] . This phenomenon was not detected with lymphocytes from patients with Type 2 (non-insulin dependent) diabetes or with other autoimmune diseases. It was specifically blocked by B-cell membrane extracts, by preabsorption of lymphocytes with B cells, or by anti-CD3 monoclonal antibodies [11] . These previous studies were performed with human patients. In the present study, in order to establish the presence of such a marker in an animal model of Type 1 diabetes, we have evaluated the B-cell binding of splenocytes from SZ-treated mice and the T-cell subsets involved. Furthermore, the B-cell specificity of the phenomenon was confirmed using a panel of non-B cells (especially exocrine pancreatic tumoral cells, endocrine cells, natural killer (NK)-target cells). Overall, in regard to the importance of the prediabetic period, evidence for the early occurrence of this marker was investigated before the onset of hyperglycaemia and concomitantly evaluated with the develop-ment of insulitis. We did not deal with this problem in our previous work with human patients [10, 11] who were only investigated for this marker after the clinical onset of diabetes.
Island, NY, USA) supplemented with 10% FCS, penicillin (100 U/ml) and streptomycin (100 gg/ml). All experiments were performed with cells from spleens of individual mice, unless otherwise specified.
Materials and methods

Animals
CD-1 male mice (Charles River France, Saint-Aubin-les-Elbeuf, France) were obtained at 40 days of age, randomly distributed and housed under conventional conditions. They received laboratory chow and water ad libitum.
Induction of diabetes
Streptozotocin (SZ) (Upjohn Laboratories, Paris, France) was dissolved in citrate buffer (pH 4.5), and immediately injected i.p. at doses of either 40 or 33 mg.kg -~ .day -a, between 09.00 and 11.00 hours, during five consecutive days, for the induction of "autoimmune" diabetes or insulitis [1 ] . The day of the first injection was designated as day 1. Toxic diabetes was induced by the injection of a single dose (165 mg/kg) of SZ. Control mice were treated by the citrate buffer only.
Determination of serum glucose levels
Blood samples of non-fasted mice were drawn from the retro-orbital vein plexus at the following times: day i (just before the first SZ injection), day 8 (72 h after the last SZ administration) and every 2 days thereafter, until the end of the study (day 15). Serum glucose levels were determinated by the glucose-oxidase method.
Histological examination of pancreata
Pancreata were removed in 10% formalin, embedded in paraffin, and 5 gm sections were obtained. Every 10 th section was stained with haematoxylin-eosin or aldehyde-fuchsin to assess the incidence of inflammatory changes and the degree of islet destruction. Slides were evaluated and scored double blind. The degree of insulitis was graded as: ( -), no infiltration; ( + ), changes with lymphocytes restricted to 10% of at least 50 islets of the same pancreas ( + + ), infiltration around and within at least 30% of the islets; ( + + + ), infiltration within at least 60% of the islets. The degree of islet destruction was similary graded double blind as: ( -), no destruction; ( + ), destruction restricted to 10% of at least 50 islets of the same pancreas; ( + + ), destruction of at least 30% of the islets; ( + + + ), destruction of at least 60% of the islets. At least 5 sections were examined at varying depths for each pancreas. Results are presented as mean intensity of insulitis or degree of islet destruction in 7 pancreases for each group.
Splenocyte isolation
Spleens were removed and floated in a Hanks' balanced salt solution (HBSS) (Seromed, Berlin, FRG) with 2% fetal calf serum (FCS) (Flow Laboratories, Irvine, UK). Splenocytes were flushed from the parenchyma by the injection of 30 ml of the above HBSS-FCS. Erythrocytes were then lysed by ammonium chloride (0.17 mol/1) for 10 rain at 4 ~ This cell suspension was then washed twice and resuspended in RPMI 1640 (Gibco laboratories, Grand
Cell lines
The rat insulinoma RINm-5F [12] , the human neuroblastoma SK-N-MC [13] , melanoma SK-MEL-1 C32 [14] , exocrine pancreatic carcinoma CAPAN-1 [15] , ovarian carcinoma OVCAR-3 [16] , breast carcinoma MCF7 [17] and the rat colon carcinoma TS cell lines [18] were maintained as monolayers in RPMI-10% FCS in plastic tissue culture flasks (Falcon Labware, div., Becton Dickinson, Oxnard, Calif., USA). The hamster B-cell subclone HIT 15 [19] was grown in Ham's F12 medium (Gibco, Paisley, Scotland, UK) with 10% FCS and 1% glutamine. When confluent, cells were detached and dissociated with trypsin (0.05%)-EDTA (0.02%) (Seromed) at 37 ~ washed, resuspendedin RPMI-10% FCS, andincubated for 2 h at37 ~ experiments. The human chronic myelogenous leukemia K562 [20] , rat myeloma IR983F [21] and murine lymphoma YAC-1 cell lines were maintained in suspension culture in RPMI-10% FCS. All cell lines were grown at 37 ~ in a humidified atmosphere of air: CO2 (95 %: 5 %). RIN cells were used at culture passages less than 75, when more than 10% of these cellswere stillstained with A2B5 monoclonal antibody (SERA-Lab, Sussex, UK) in an indirect immunofluorescence (IF) assay (data not shown).
Rosette-forming cell (RFC) assay
The numeration of splenocytes binding to target cells was performed with a method slightly modified from that previously described for human blood lymphocytes [10] . Briefly, 1.5 • 106 splenocytes and 2 • 105 irradiated (3000 rads) target cells (B or non B) were co-incubated in 1 ml of RPMI-10% FCS into 5 ml polypropylene culture tubes (Sarstedt, Rommelsdorf, Numbrecht, FRG) at 37 ~ in a 5% CO2 atmosphere for 48 h. After a careful homogenization, aliquots of the cell mixture were deposed into a Malassez counting chamber. Splenocytes bound and not bound to target cells were simultaneously counted under light microscopy. The whole grid area was scanned. Results are transformed into the total number of target-adherent splenocytes among the total number of splenocytes initially seeded in each tube. Each mouse was tested in triplicate (intra-assay variability always less than 10%. Control and SZ-treated mice were always tested simultaneously in each experiment. In some experiments, increasing numbers of splenocytes were incubated with a constant number (2 x 105) of RIN cells (splenocytes/RIN ratios: 1 : 1, 3 : 1, 7.5 : 1, 10 : 1, 20 : 1), before the enumeration of cytoadherent spleen cells.
To assess the effects of a T cell mitogen, splenocytes from SZtreated or control mice were seeded for 2 days into round-bottomed 96-well plates in RPMI-10% FCS containing concanavalin A (ConA) (Sigma, St.Louis, Mo, USA) at a final concentration of 2 gg/ml. Splenocytes were then washed, counted, and assayed for their binding ability to RIN cells in the RFC assay as described above.
To test the possibility that the RIN-binding ability of splenocytes is FC-receptor/antibody-mediated, heat-aggregated (63 QC; 30 min) mouse IgG (20 gg/ml) were added to splenocytes 1 h before the addition of RIN cells in the RFC assay.
RFC assay after depletion of T cell subsets
Splenocytes from control and SZ-treated mice were depleted from macrophages by incubation on plastic Petri dishes (Nunc, Rostkilde, Denmark, 15 x 106/dish) for 2 h at 37 ~ in RPMI-10% FCS, and the loss of adherent spleen cells was similar in SZ-treated and control 
Statistical analysis
All data are presented as mean values + SEM. The statistical significance of the differences between the experimental groups was evaluated using the Student's t-test or the non parametric Mann-Whitney U test when n < 5. p < 0.05 was considered as significant. The least-squares linear regression was used for correlation analysis.
Results
RIN-adherence of splenocytes from low-dose SZ-treated mice
The number of RIN-adherent splenocytes was significantly higher in SZ(40 mg. kg ~. day-1)-treated mice (n = 14) analysed by the 10 th day after the first injection of SZ than in control (n= 15) mice (respectively, 13 728+622 vs 8581 + 415; p < 0.0001) (Fig. 1 ). This significant difference between SZ-treated and control mice was detectable from 24 h of co-incubation and persisted after 48 h and 72 h (data not shown). When increasing splenocytes/RIN ratios in the RFC assay, the percent of RIN-binding splenocytes was significantly (p < 0.01) higher in SZ-treated than in control mice only at lower splenocytes/RIN ratios (1.5% vs 0.9% at 1 : 1; 1.4% vs 0.6% at3 : 1; and 0.9% vs 0.6% at7.5 : 1). At higher ratios (10" 1, 20 : 1), the percent of RIN-binding splenocytes fell in SZ-treated mice to that of control splenocytes which remained constant (Fig. 2) .
Target-cell specificity of cytoadherence
Simultaneous with the above difference in the RIN-binding ability, the number of splenocytes adherent to B-HITcells was similarly higher in SZ-treatedmice than in control mice (Fig. 3) . By contrast, no statistical difference was observed between SZ-treated and control mice in the number of splenocytes adhering to a panel of 9 non-B cell lines (Fig. 3) . In particular, no difference was observed on exocrine pancreatic CAPAN cells, on cells ofneuroectodermic origin (melanoma SK-MEL-1-C32, neuroblastoma SK-N-MC), or on NK-target cells (YAC-1, K562).
RIN-binding splenocytes precede the onset of diabetes and of insulitis
The number of RIN-adherent splenocytes of SZ-injected mice was not different from that of control animals (Fig. 4) when examined by the 2 nd day of SZ (40 mg-kg -1. day-1)_ treatment when overt insulitis had not yet been observed. This number increased significantly (p < 0.01) above control values as early as the day of final SZ-administration when no hyperglycaemia was found. At this time, only a mild islet destruction ( + ) was detectable (Fig. 4) . This rise in the number of RIN-binding lymphocytes by the 5 th and the 10 th day after the final SZ-injection concomitantly with the occurrence of insulitis and then with the onset of hyperglycaemia (Fig. 4) .
Correlation between the number of RIN-adherent splenocytes and the onset of diabetes or glycaemic levels
No correlation could be found between the number of RIN-binding lymphocytes and glycaemia in SZ (40 mg. kg-1. day-~)-treated mice examined at day 10, some mice even displaying a high number of RIN-binding spleno- . Asterisks denote statistical differences between SZ-treated and control mice: * p < 0.01. Simultaneously, the pancreata were scored for insulitis and islet destruction as mentioned in the table below the figure. Fourteen animals were included at each point cytes without any hyperglycaemia (Fig. 5) . Moreover, injections of lower doses (33 mg. kg-a. day -~) of SZ led to a significantly (p < 0.01) increased number of RIN-binding splenocytes by 5 days after the last SZ injection (Fig.5) , while these animals remained normoglycaemic (9.0 + 0.6 mmol/1, n = 26) but while insulitis was noted with an incidence of 50%. Conversely, the number of R1N-adherent splenocytes remained at control levels in mice displaying a single "toxic" dose (165mg/kg) SZ-induced diabetes without insulitis (Fig.5) . Consequently, when low-dose (40 and 33 mg.kg -~-day -a) and high-dose SZ-treated mice were simultaneously analysed with control mice (Fig.5) , numbers of RIN-adherent splenocytes did not correlate with blood glucose levels. 
RFC-assay after depletion of lymphocyte subsets, after T cell stimulation, or after blocking of the FC-receptor
After depletion of T-lymphocytes by monoclonal antibodies directed against the Thy 1-2 antigen, the number of RIN-adherent splenocytes from SZ (40mg.kg -~. day-a)-treated mice was reduced by 42.2%, falling to control levels (Fig. 6 ). Figure 6 also shows that depletion of either L3T4 + or Lyt2 + subsets reduced (p<0.01) the RIN-binding ability of splenocytes from SZ-treated mice ( -26.5% and -31.5%, respectively). Con A-stimulated splenocytes from SZ-treated mice displayed a higher (p < 0.01) RIN-binding ability (14 968 + 819) than control splenocytes stimulated (10 970 + 689) or not (9076 + 628) by the T cell mitogen (n = 4).
In the presence of aggregated IgG, the number of RINadherent splenocytes was still higher (p < 0.01) in SZtreated mice (13 158 + 741; n = 4) than in control mice (8500 + 574; n = 4).
Discussion
We have demonstrated in vitro that the increased B-cell adherence of lymphocytes, previously described in human Type i diabetes [10, 22] , is also found during low-dose SZinduced diabetes in mice. Overall, this phenomenon precedes the clinical onset of diabetes, and even the overt insulitis. It seems more closely linked to insulitis than to hyperglycaemia. Furthermore, we suggest that this cytoadherence may be B-cell specific and involves L3T4 § and Lyt2 + T lymphocyte subsets.
This RIN-binding ability of splenocytes from SZtreated mice appears B-cell-specific, since a similar increase was observed on another B cell line (HIT cells), but not on 9 non-B cell lines. Particularly, this marker was not detected on exocrine pancreatic cells or on NK-target cells. Experiments with increasing splenocytes/RIN ratios confirm that the phenomenon may be specific for splenocytes from SZ-treated mice. Indeed, it was only detectable at lower splenocyte/RIN ratios, and not at higher ratios when "specific target receptors" on RIN-cells may have been "hidden" by a high number of splenocytes non-specific for B cells. During the same experiments, the % of control splenocytes involved in RIN-conjugates remained nearly constant thoroughly the ratio scale, probably be cause no Bcell specific lymphocytes were present. Splenocytes from SZ-injected mice binding specifically to B cells may represent, as in human diabetic patients [10] , a marker of cellmediated immunity, since they appear to be mainly composed of T-lymphocytes, as suggested by depletion experiments of lymphocyte subsets. These T-cells include both L3T4 + (CD4 +) and Lyt2 § (CD8 +) lymphocytes. One can note that only CD4 + (and not CD8 +) were demonstrated in the increased B-cell binding oflymphocytes from human Type 1 diabetic patients [10, 11] . The reason for this discrepancy is not clear, but any comparison between blood lymphocytes (in human patients) and spleen cells (in SZtreated mice) should be cautious since spleen lymphocytes can have different qualitative and quantitative features from those in peripheral blood, even in a given species. On the other hand, these results are consistent with the immunocytochemical characterization of numerous L3T4 + and Lyt2 + cells in SZ-induced insulitis [4, 6] . The major pathogenetical role of these two lymphocyte subsets is also emphasized by immune intervention trials showing prevention of SZ-induced diabetes by monoclonal antibodies directed against these differentiation antigens [4] . Direct activation of the T cell compartment is thought to mediate at least part of the diabetogenic effect of low dose SZ since this treatment induces T cell stimulation and the secretion of lymphokines, particularly IFN-7, and systemic MHC induction [23] . However, these direct effects of SZ on T cells are not likely to be sufficient to explain the increased B-cell adherence of lymphocytes from low-dose treated mice. Firstly, because in vitro activation of T cells by Con A was not sufficient, in our hands, to increase the RIN-binding ability of splenocytes from control mice to the level observed in low-dose SZ-treated mice. Secondly, because if this increased binding ability was only due to the direct effect of SZ on lymphocytes, it would probably be detectable whatever the target cells (B or non-B) . In that respect, we 13 emphasize the fact that the adherence of splenocytes from SZ-treated mice was not increased on 9 non-B cell lines. These latter results suggest that the increased B-cell binding of lymphocytes from SZ-injected mice also involved a specific recognition of B-cell molecules.
If this hypothesis is correct, then the recognition of Bcell antigens by T-lymphocytes takes place in a xenogenic context, thus raising the problem of the apparent absence of restriction by MHC molecules, even if there is increas 2 ing evidence that this dogma is too absolute. Indeed, non-MHC-restricted T cells have now been described [24] [25] [26] [27] . In regard to autoimmune diseases, CD8 § T cells from Type 1 diabetic patients specifically inhibited insulin release from xenogeneic islet cells [28] , and non-MHCrestricted tissue-specific T cells recognized autologous oligodendrocytes in mice [29] .
Alternatively, the B-cell specific adherence observed in our study may be due to B-cell adhesion molecules for lymphocytes. Such molecules, called "addressins" may be involved in selective homing or migration [30] . One can note that the expression of intercellular adhesion molecule has been preliminarily documented in human pancreatic islets [31] .
On the other hand, the fact that aggregated IgG did not abolish the increased adhesion of splenocytes from SZtreated mice to B cells suggests that this binding is not FCreceptor/antibody mediated.
Nevertheless, the prevailing fact of the present study remains that RIN-specific binding became detectable 5 days before the occurrence of hyperglycaemia induced by SZ (40 mg. kg -1. day-1), and is, thus, an early dysfunction during the prediabetic stage in this animal model. This phenomenon also slightly precedes the overt insulitis, although it is impossible to compare it with the earlier "single cell insulitis" [32] . This early implication of cellular immunity may occur closer to the time of detection of islet cell surface antibodies, and before hyperglycaemia in SZ-treated mice [33] . Our preliminary data similarly suggest the presence of RIN-specific binding lymphocytes in some humans at high risk for Type i diabetes [34] .
No RIN-specific binding was found with splenocytes from mice becoming diabetic following a single toxic-dose of SZ (165 mg/kg), when no insulitis but only a B-cell necrosis is observed. Conversely, using the subdiabetogenic SZ-dose of 33 mg. kg 1. day-1 unable to induce hyperglycaemia, the RIN-specific adherence of MNC was detectable while insulitis was frequently present. All these data put together suggest that the increased RIN-adherence of splenocytes is rather correlated with the presence of insulitis than with hyperglycaemia.
In summary, we have demonstrated a new marker of cellular immunity in low-dose SZ-induced diabetes. It seems B-cell specific and is rather linked to the insulitis than to the hyperglycaemia. Overall, this marker precedes the onset of clinical diabetes and is, thus, an early dysfunction during the prediabetic period in this animal model of Type i diabetes.
